Jennison Associates LLC Fate Therapeutics Inc Transaction History

Jennison Associates LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 08, 2022	SELL	$47.84 - $64.34 $18.4 Million - $24.7 Million	-383,714 Closed	0 $0
Q3 2021 Nov 09, 2021	SELL	$59.27 - $95.73 $21.4 Million - $34.5 Million	-360,278 Reduced 48.42%	383,714 $22.7 Million
Q1 2021 May 11, 2021	SELL	$72.16 - $117.4 $2.26 Million - $3.68 Million	-31,365 Reduced 4.05%	743,992 $61.3 Million
Q4 2020 Feb 05, 2021	SELL	$38.09 - $100.95 $9.17 Million - $24.3 Million	-240,712 Reduced 23.69%	775,357 $70.5 Million
Q3 2020 Nov 04, 2020	BUY	$30.41 - $40.5 $110,814 - $147,582	3,644 Added 0.36%	1,016,069 $40.6 Million
Q2 2020 Aug 06, 2020	SELL	$20.21 - $35.23 $2.16 Million - $3.77 Million	-106,950 Reduced 9.55%	1,012,425 $34.7 Million
Q1 2020 May 06, 2020	SELL	$17.28 - $31.88 $3.24 Million - $5.98 Million	-187,631 Reduced 14.36%	1,119,375 $24.9 Million
Q4 2019 Feb 07, 2020	BUY	$13.39 - $20.73 $102,272 - $158,335	7,638 Added 0.59%	1,307,006 $25.6 Million
Q3 2019 Nov 08, 2019	BUY	$15.47 - $22.5 $11.6 Million - $16.9 Million	751,446 Added 137.14%	1,299,368 $20.2 Million
Q2 2019 Aug 06, 2019	BUY	$15.61 - $20.44 $950,305 - $1.24 Million	60,878 Added 12.5%	547,922 $0
Q1 2019 May 10, 2019	BUY	$13.15 - $18.71 $3.33 Million - $4.74 Million	253,540 Added 108.58%	487,044 $8.56 Million
Q4 2018 Feb 06, 2019	SELL	$11.48 - $16.98 $763,374 - $1.13 Million	-66,496 Reduced 22.17%	233,504 $3 Million
Q3 2018 Nov 08, 2018	BUY	$8.75 - $16.29 $2.63 Million - $4.89 Million	300,000 New	300,000 $4.89 Million

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $181M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Jennison Associates LLC, based on Form 13F filings with the SEC.

Stay updated on Jennison Associates LLC with notifications on news.